PR3/MPO-ANCA is as effective as immunofluorescence as a first-line test in AAV screening
|
|
- Jessie Brooks
- 6 years ago
- Views:
Transcription
1 PR3/MPO-ANCA is as effective as immunofluorescence as a first-line test in AAV screening Stephen Holding PhD FRCPath Consultant Clinical Scientist Hull & East Yorkshire Hospitals steve.holding@hey.nhs.uk +44 (0)
2 Declaration of interest Biorad Laboratories have contributed to costs to enable SH to attend The 17 th International Vasculitis & ANCA Workshop.
3 Consensus Statement Consensus statement (1999) Addendum to Consensus Statement (2003) 1. Patient selection 2. Structured testing protocol 3. Defined methods and quality control 4. Appropriate report comments Savige J et al. Am J Clin Pathol 1999;111: Savige J et al. Am J Clin Pathol 2003;120:
4 Consensus Statement Minimum: Test all samples by IFT on ethanol fixed neutrophils. All new positive IFT must have PR3-ANCA and MPO-ANCA performed. Savige J et al. Am J Clin Pathol 1999;111:
5 Test Performance Proportion of patients with AAV IFT Pos Neg Total EIA Pos 72% 8% 80%* Neg 9% 11% 20% Total 81% 19% 100% *between 76% and 84% Based on data extracted from: Hagen EC et al. Kidney International 1998;53: Savige J et al. Am J Clin Pathol 1999;111:
6 Changes Since the Consensus Documents IFT is essentially unchanged Microscopes have improved More use of standardised reagents and commercial slides PR3/MPO-ANCA methods Improved comparability between assays though quantitative results are not comparable. Direct EIA (antigen coated solid phase) Capture EIA (typically solid phase antibody capture of a soluble antigen) Anchor or hseia (using a bridging molecule to attach the antigen to the solid phase) Improvements in automation Multiplex assays may provide additional antigens in the future Revised Chapel Hill consensus on nomenclature of Vasculitides (Arthritis Rheum 2013;65:1-11)
7 Hull ANCA testing protocol Screen using IFT. Euroimmun ANCA slides (ethanol fixed neutrophils and separate HEp2 cells). PR3-ANCA and MPO-ANCA on all positive IIF-ANCA (C-ANCA, P-ANCA, atypical ANCAs and ANA positive). Biorad BioPlex 2200 multiplex assay
8 Assessing the effect of changing to EIA 1 st (i) Retrospective review of outcomes from IFT positive, EIA negative samples. The patients that would be missed in an EIA 1 st approach. (ii) Retrospective review of clinical outcomes for all ANCA test requests. Enables accurate assessment of sensitivity in a specific clinical setting. (iii) Assessment of specificity in routine use.
9 EIA Sensitivity for AAV - Hull Study (i) Retrospective review of outcomes from IFT positive, EIA negative samples All IFT positive, EIA (PR3/MPO) negative samples: All screens from current protocol (02/2011 to 02/2014): 8985 consecutive IFT ANCA screens 4060 consecutive PR3/MPO-ANCA tests 101 C-ANCA (69 EIA +ve) & 36 P-ANCA (14 EIA +ve) Findings: 32 C-ANCA +ve, EIA ve. 3 known AAV (3 patients), 29 no evidence of AAV. 22 P-ANCA +ve, EIA ve. 3 known AAV (2 patients), 19 no evidence of AAV. All 5 of the known patients had positive EIA at presentation. 452 atypical ANCA, EIA ve (random selection of 89 reviewed). 36 known AAV (16 patients), 53 no evidence of AAV. All 16 known AAV patients had positive EIA at presentation. Conclusion: No missed new diagnoses if EIA 1 st approach used.
10 Sensitivity for AAV - Hull Study (ii) Retrospective review of outcomes for all ANCA tests Sample source mainly rheumatology, renal, chest medicine, ENT, dermatology (review of diagnosis for all ANCA requests): Prospective testing of samples, diagnosis from casenotes. 16 new patient presentations with AAV (10 GPA; 3 MPA; 3 EGPA) n IFT Clinical Sensitivity PR3- ANCA PR3/MPO-ANCA MPO- ANCA PR3 or MPO ANCA GPA 10 90% (100%) 70% 30% 100% MPA 3 0% (100%) 0% 100% 100% EGPA 3 0% (33%) 0% 33% 33% Any AAV 16 56% (88%) 44% 44% 88%
11 Summary Sensitivities IFT 1st EIA 1st n GPA 100% 100% 10 MPA 100% 100% 3 EGPA 33% 33% 3 All AAV 88% 88% 16 Conclusion: IFT 1 st & EIA 1 st protocols have equivalent sensitivity.
12 Specificity (iii) Assessment of specificity for EIA 1 st in routine use 343 patient samples tested for PR3/MPO-ANCA by Biorad BioPlex 2200 Luminex based Multiplex assay. 17 positive by EIA 8 with a diagnosis of AAV 9 with no evidence of AAV Specificity = (343-8)-9 (343-8) = 97% (95% confidence interval = 95% - 99%) Conclusion: Specificity of an EIA 1 st protocol is very good
13 PR3/MPO-ANCA is as effective as immunofluorescence as a first-line test in AAV screening. Summary Studies informing the Consensus Statement showed similar efficacy for IFT 1 st and EIA 1 st approaches. EIA method reliability, sensitivity and comparability have improved since the consensus statement was agreed (i) Retrospective review of outcomes from IFT positive, EIA negative samples showed no clinically significant false negative EIA results. (ii) Retrospective review of outcomes for all ANCA tests Showed sensitivity of EIA 1 st & IFT first protocols to have similar sensitivity for AAV (88%). (iii) Assessment of specificity in routine use Specificity for AAV was excellent (97%).
14 Acknowledgements Dr Mohamed Abuzakouk Immunology & HYMS, Hull Dr Sathish Kallankara Rheumatology, Hull Dr Tim Rowland Chest Medicine, Hull Dr Vicky Fisher Vascular Surgery, Hull Dr Simon Hart Chest Medicine & HYMS, Hull Hull Hospitals Patient Coding Team Hull Hospitals/HYMS Vasculitis Research Group
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin
More informationANTI NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) TESTING GUIDELINES
ANTI NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) TESTING GUIDELINES Version: 1.0 Ratified by: Clinical Biochemistry Senior Staff Group Date ratified: Name of originator/author: Director responsible for implementation:
More informationSimultaneous comprehensive multiplex autoantibody analysis by CytoBead technology for Rapidly Progressive Glomerulonephritis.
Simultaneous comprehensive multiplex autoantibody analysis by CytoBead technology for Rapidly Progressive Glomerulonephritis l Assays Indirect Immunofluorescence Goldstandard for Diagnosis of Autoimmune
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationSHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth
SHO Teaching Vasculitis Renal medicine Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth OUTLINE What is vasculitis Causes Classification Brief look into ANCA Associated Vasculitis (AAV)
More informationA Dual-Fixed Neutrophil Substrate Improves Interpretation of Antineutrophil Cytoplasmic Antibodies by Indirect Immunofluorescence
AJCP / Original Article A Dual-Fixed Neutrophil Substrate Improves Interpretation of Antineutrophil Cytoplasmic Antibodies by Indirect Immunofluorescence Ming-Wei Lin, MBBS, 1,2 Roger A. Silvestrini, 1
More informationUpdates from the 15 th ANCA workshop
Updates from the 15 th ANCA workshop Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France Nataliya Milman, MD Ottawa, Canada Simon Carette, MD, MPhil, FRCP
More informationanti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
More informationDiagnostic Value of Distinguishing and Reporting Different Perinuclear ANCA (P-ANCA) Immunofluorescence Patterns A Prospective Study
Diagnostic Value of Distinguishing and Reporting Different Perinuclear ANCA (P-ANCA) Immunofluorescence Patterns A Prospective Study CME/SAM Susan B. Perel, MBBS, FRACP, FRCPA, 1,2 Kerri M. Prain, 1 Robert
More informationVASCULITIS PRODUCT HIGHLIGHTS
VASCULITIS PRODUCT HIGHLIGHTS AESKU.DIAGNOSTICS offers a comprehensive and complete diagnostic portfolio in the field of vasculitis diagnostics. Not only are screening and profiling s available but also
More informationPlasma exchanges in ANCA-associated vasculitis
Plasma exchanges in ANCA-associated vasculitis Xavier Puéchal, MD, PhD Centre de Référence des Maladies auto-immunes systémiques rares d Ile de France Hôpital Cochin Université Paris Descartes http://www.vascularites.org
More informationAssays. New. New. Combinations. Possibilities. Patents: EP , AU
Assays Patents: EP 2362222, AU 2011217190 New Combinations New Possibilities Technology Classical Handling of Autoimmune Diagnostics 2-Step Diagnostics 1 st Screening 2 nd Confirmation Cell based IFA ELISA
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Update on Granulomatosis with Polyangiitis (Wegener s) Learning Objectives Identify the clinical features of granulomatosis with
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationVasculitis of the peripheral nervous system
4 rd Congress of the European Academy of Neurology Lisbon, Portugal, June 16-19, 2018 Teaching Course 5 Acute emergencies in neuromuscular disease - Level 2 Vasculitis of the peripheral nervous system
More informationEDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link
EDITORIAL, October 2004 Welcome to the Spring 2004 Edition of InfoLink. The feature article in this edition has been written by Dr Rodger Laurent, Head of Department, PaLMS Rheumatology Laboratory. The
More informationSmall Vessel Vasculitis
Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk
More informationAN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS
GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?
More informationUniversity of Groningen
University of Groningen Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis Bossuyt, Xavier; Tervaert, Jan-Willem Cohen; Arimura, Yoshihiro;
More informationSmall Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
More informationOlder patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study
Manno et al. BMC Nephrology (2015) 16:88 DOI 10.1186/s12882-015-0082-9 RESEARCH ARTICLE Open Access Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS
TREATMENT OF ANCA-ASSOCIATED VASCULITIS Loïc Guillevin Hôpital Cochin, Université Paris Descartes Cours DU, 11 mars 2016 1 Disclosure of interest regarding this presentation Roche has provided, in part,
More informationEliA MPO S and EliA PR3 S
Edition 1 2011 n Review ANCA and associated diseases n The Assays EliA MPO S and EliA PR3 S n Experience ANCA testing by high sensitive methods CONTENTS Editorial Some months ago a Swiss colleague sent
More informationClinical research in adult vasculitis. Calgary October 8 th, 2015
Clinical research in adult vasculitis Calgary October 8 th, 2015 Disclosures Consulting and speaker fees Hoffmann-La Roche BMS Advisory boards Hoffmann-La Roche GSK Educational subventions (CanVasc) Hoffmann-La
More informationSMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018
SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018 OUTLINE Renal involvement in vasculitis Curr Rheumatol Rep 2013 Renal involvement in ANCA vasculitis GN***:
More informationNew biomarkers for ANCA-associated Vasculitis? Juliana Bordignon Draibe
New biomarkers for ANCA-associated Vasculitis? Juliana Bordignon Draibe Summary Introduction Antibodies: ANCAs, Anti-LAMP-2, Anti-moesin B and T lymphocytes Markers of vascular activation: complement,
More informationComplement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna
Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary
More informationManaging Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
More informationTell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital
Tell me more about vasculitis Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital Talk overview Case study ANCA-associated vasculitis What is ANCA vasculitis? What causes ANCA
More informationDisease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia
International Journal of Clinical Rheumatology Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia Background: ANCA-associated vasculitis (AAV) is a potentially
More informationEULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
More informationCase Report Testicular Vasculitis: A Sonographic and Pathologic Diagnosis
Hindawi Case Reports in Radiology Volume 2017, Article ID 8923621, 4 pages https://doi.org/10.1155/2017/8923621 Case Report Testicular Vasculitis: A Sonographic and Pathologic Diagnosis Anuj Dixit, 1 Cameron
More informationAbstract. Immunopathology / ADDENDUM TO CONSENSUS STATEMENT ON TESTING AND REPORTING OF ANCA
Immunopathology / ADDENDUM TO CONSENSUS STATEMENT ON TESTING AND REPORTING OF ANCA Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies Quality
More informationDiagnostic Procedures for Vasculitis
Diagnostic Procedures for Vasculitis Toshiharu Matsumoto, MD Clinical Professor of Department of Diagnostic Pathology Juntendo University Nerima Hospital, Tokyo, Japan Introduction In 1994, the International
More informationVasculitis Prof. Dr. med. Katharina Glatz Pathologie
Vasculitis 08-21-2018 Prof. Dr. med. Katharina Glatz Pathologie Agenda Anatomy and histology Vasculitis: Chapel Hill Classification Examples Giant cell arteritis Single organ vasculitis Artery or Vein?
More informationV asculitis is an inflammatory process of blood vessels,
723 ORIGINAL ARTICLE Cinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre
More informationReview Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar
Review Article Vidarbha Journal of Internal Medicine Volume 23 July 207 Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis Milind Aurangabadkar ABSTRACT Anti-neutrophil
More informationPAEDIATRIC VASCULITIS
PAEDIATRIC VASCULITIS Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. OUTLINE Introduction
More informationRenal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis
Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis E.S. Park, S.S. Ahn, S.M. Jung, J.J. Song, Y.-B. Park, S.-W. Lee Division of Rheumatology, Department of Internal
More informationAntineutrophil Cytoplasmic Antibodies: Historical perspectives and new advances
INOVA NEWS Antineutrophil Cytoplasmic Antibodies: Historical perspectives and new advances First described in 1982, antineutrophil cytoplasmatic antibodies (ANCA) represent a diagnostically important group
More informationANCA serology in the diagnosis and management of ANCA-associated renal vasculitis GUIDELINES
NEPHROLOGY 2008; 13, S17 S23 ANCA serology in the diagnosis and management of ANCA-associated renal vasculitis Date written: June 2007 Final submission: October 2007 Author: Grant Luxton, Robyn Langham
More informationAnti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease
Anti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease Grace M. Lee, Yara A. Park, Marshall Mazepa, Jay S. Raval Introduction Anti-neutrophil
More informationEudraCT number: Page 8 of 42
EudraCT number: 2012-001102-14 Page 8 of 42 5 Trial Synopsis Title Sponsor name North American Sponsor Disease Under Investigation An international, open label, randomised, controlled trial comparing rituximab
More informationIntermediate monocytes in ANCA vasculitis: increased surface. expression of ANCA autoantigens and IL-1β secretion in response. to anti-mpo antibodies
Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-mpo antibodies Eóin C. O Brien 1, Wayel H. Abdulahad 2, Abraham Rutgers
More informationImmune-mediated lung disease. Ian Sabroe
Immune-mediated lung disease Ian Sabroe It s all immune? Diseases that doesn t have immune involvement? The processes of response to injury and tissue repair are key homeostatic pathways involved in all
More informationRepeat protocol renal biopsy in ANCA-associated renal vasculitis
NDT Advance Access published February 26, 2014 Nephrol Dial Transplant (2014) 0: 1 5 doi: 10.1093/ndt/gfu042 Original Article Repeat protocol renal biopsy in ANCA-associated renal vasculitis Zdenka Hruskova
More informationDifferentiated ANCA diagnostics using BIOCHIP Mosaics
Differentiated ANCA diagnostics using BIOCHIP Mosaics Gran. MPO microdoplet Example: Antibodies against MPO and homogeneous ANA pattern Anti-MPO? ANA? panca positive, anti-mpo positive gran. Final result:
More informationEvidence-based therapy for the ANCAassociated vasculitides: what do the trials. show so far? Clinical Trial Outcomes
associo far? Evidence-based therapy for the ANCAassociated vasculitides: what do the trials show so far? Anti-neutrophil cytoplasm antibody-associated vasculitides are rare multisystem inflammatory diseases
More informationDiagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns
124 Immunopathology Department, ICPMR, Westmead Hospital, NSW 2145, Australia RCWWong R A Silvestrini D A Fulcher E M Benson University Department of Medicine, Austin and Repatriation Medical Centre, Heidelberg,
More information4. KIDNEYS AND AUTOIMMUNE DISEASE
How to Cite this article: Kidneys and Autoimmune Disease - ejifcc 20/01 2009 http://www.ifcc.org 4. KIDNEYS AND AUTOIMMUNE DISEASE Maksimiljan Gorenjak 4.1 Autoimmune diseases The human immune system limits
More informationRituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
More informationNew Developments in ANCA-associated Vasculitis
New Developments in ANCA-associated Vasculitis Second International Renal Conference Bruges, March 2018 Ulrich Specks, M.D. Connor Group Foundation Professor of Medicine Mayo Clinic College of Medicine
More informationComparison of Performance of ELISA with Indirect Immunofluoresence for the Testing of Antinuclear Antibodies
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 12 (2016) pp. 423-427 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.512.046
More informationRelation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis
Houben et al. BMC Nephrology (2017) 18:378 DOI 10.1186/s12882-017-0797-x RESEARCH ARTICLE Open Access Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis Eline
More informationEudraCT number: Page 9 of 46
EudraCT number: 2012-001102-14 Page 9 of 46 5 Trial Synopsis Title Sponsor name North American Sponsor Japan Sponsor Ireland Sponsor Disease Under Investigation An international, open label, randomised,
More informationCombined Infliximab and Rituximab in Necrotising Scleritis
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationAvacopan in addition to standard of care for ANCA-associated vasculitis
EVIDENCE BRIEFING DECEMBER 2018 Avacopan in addition to standard of care for ANCA-associated vasculitis NIHRIO ID 24160 NICE ID 10023 Developer/Company ChemoCentryx and Vifor Pharma UK Ltd UKPS ID N/A
More informationPhysiopathologie des vascularites associées aux ANCA
Physiopathologie des vascularites associées aux ANCA Benjamin Terrier Centre de Référence pour les Maladies AutoImmunes Systémiques Rares Hôpital Cochin, Université Paris Descartes Paris, France Fibrinoid
More informationPersistent hematuria in patients with. vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?
Lv et al. BMC Nephrology (2017) 18:354 DOI 10.1186/s12882-017-0763-7 RESEARCH ARTICLE Open Access Persistent hematuria in patients with antineutrophil cytoplasmic antibodyassociated vasculitis during clinical
More informationJournal of Nephropathology
www.nephropathol.com DOI: 10.15171/jnp.2017.16 J Nephropathol. 2017;6(2):97-102 Journal of Nephropathology Differences in the frequency of macrophage and T cell markers between focal and crescentic classes
More informationCitation for published version (APA): Chen, M. (2009). Pathogenetic and clinical aspects of ANCA-associated vasculitis Groningen: s.n.
University of Groningen Pathogenetic and clinical aspects of ANCA-associated vasculitis Chen, Min IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationAntineutrophil cytoplasm antibody associated vasculitis: recent developments
mini review http://www.kidney-international.org & 2013 International Society of Nephrology Antineutrophil cytoplasm antibody associated vasculitis: recent developments Shunsuke Furuta 1 and David R.W.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jones RB, Cohen Tervaert JW, Hauser T, et al. Rituximab versus
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationEUVAS update June 5 th Marinka Twilt
EUVAS update June 5 th 2012 Marinka Twilt Chapel Hill 2012 Classification Large Vessel Vasculitis (LVV) Medium Vessel Vasculitis (MVV) Small Vessel Vasculitis (SVV) Variable Vessel Vasculitis (VVV) Single
More informationVasculitis Update. A selective review of what s new. Dr Jonathan Akikusa MBBS FRACP
Vasculitis Update A selective review of what s new Dr Jonathan Akikusa MBBS FRACP Consultant Paediatric Rheumatologist Royal Children s Hospital, Melbourne Honorary Research Fellow Murdoch Children s Research
More informationANCA Associated vasculitis presenting as bilateral pleural effusion: A rare case report
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Case Report Volume 3, Issue 10-2017 DOI: http://dx.doi.org/10.22192/ijcrms.2017.03.10.015
More informationAdvances in Laboratory Testing for Rheumatic Diseases Updates in Testing for Rheumatic Diseases. The ABIM s view of rheumatologic lab testing
The black hole of medical knowledge: An internist s view of rheumatologic lab tests Advances in Laboratory Testing for Rheumatic Diseases 2010 Jonathan Graf, M.D. Assistant Clinical Professor of Medicine
More informationRate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis
Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis M. Jung 1, L. Barra 2 1 Division of Rheumatology, Department of Medicine, University
More informationUpdate and Review on Vasculitis. Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015
Update and Review on Vasculitis Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015 Outline Classification and nomenclature updates Small vessel vasculitis Pathophysiology Diagnosis Management/therapeutic
More informationVasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura)
Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura) J. Charles Jennette Ronald J. Falk The kidneys are affected by a variety of systemic vasculitides
More informationChapter 2 Animal Models of ANCA-Associated Vasculitides
Chapter 2 Animal Models of ANCA-Associated Vasculitides Domenico Ribatti and Franco Dammacco Abstract Antibodies against neutrophil proteins myeloperoxidase (MPO) and proteinase- 3 (PR3) are responsible
More informationScreening of Auto Antibodies using Indirect Immunofluorescence in Auto Immune Disease Patients
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 02 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.702.386
More informationGOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS
GOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS VESNA JURČIĆ 1, ANDREJA ALEŠ RIGLER 2, INSTITUTE OF PATHOLOGY, FACULTY OF MEDICINE, UNIVERSITY
More informationNOVA Lite ANCA (Ethanol) Kit with DAPI For In Vitro Diagnostic Use CLIA Complexity: High
Format to CLSI Standards GP2-A5 (Formerly NCCLS) Vol. 26 No. 12 Issue Date: 09/11/13 NOVA Lite ANCA (Ethanol) 708301 Kit with DAPI For In Vitro Diagnostic Use CLIA Complexity: High Principles of the Procedure
More informationLong-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
Rheumatology 2008;47:1515 1520 Advance Access publication 1 August 2008 doi:10.1093/rheumatology/ken321 Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated
More informationMohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward
VASCULITIS SYNDROMES Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward ILLUSTRATED CASE 1 A 56 years old lady refered me for prolonged fever, arthritis
More informationAKI Case study -Vasculitis. Sarah Mackie Renal Practice Development Nurse King s College Hospital - London
AKI Case study -Vasculitis Sarah Mackie Renal Practice Development Nurse King s College Hospital - London What is vasculitis Vasculitis refers to inflammation of the blood vessels, including arteries,
More informationInternational Consensus Statement on Testing and
I m m u n o p a t h o l o g y / TESTING FOR A N C A S International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) Key Words: ANCA; Autoantibodies; Glomerulonephritis;
More informationInternational Consensus Statement on Testing and
I m m u n o p a t h o l o g y / TESTING FOR A N C A S International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) Judy Savige, MB, PhD, David Gillis, MB,
More informationTREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014
TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE Loïc Guillevin Hôpital Cochin, Université Paris Descartes DU MALADIES SYSTEMIQUES, 7 March 2014 1 Disclosure of interest regarding this presentation Former
More informationANCA+ VASCULITIDES CYCAZAREM,
ANCA+ VASCULITIDES CYCAZAREM, q Comparison of 3 to 6 mo. oral CYC + CS then azathioprine or oral CYC for 12 mo.+ 10 mg/d CS. After 12 mo all the patients were treated with azathioprine q 150 patients followed
More informationJones slide di 23
1 di 23 The patient with ANCA- associated vasculitis and pulmonary haemorrhage Rachel B Jones, Cambridge, UK Chairs:Hans-Joachim Anders, Munich, Germany Vladimir Tesar, Prague, Czech Republic Prof. Rachel
More informationChanges in urinary metabolomic profile during relapsing renal vasculitis
Changes in urinary metabolomic profile during relapsing renal vasculitis Bahjat Al Ani 1,3, Martin Fitzpatrick 2, Hamad Al Nuaimi 1, Alice M Coughlan 4, Fionnuala B Hickey 4, Charles D Pusey 5, Caroline
More informationDisclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None
Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies Sarah Goglin MD Assistant Professor of Medicine Division of Rheumatology Disclosures None 1 [footer
More informationANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
ANCA-associated vasculitis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas,
More informationYear In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis
Year In Review: VasculitisPers Cailin Sibley, M.D., M.H.S. Director, Vasculitis Clinic April 27 th, 2018 NTEREST DISCLOSURE Disclosures none Learning Objectives Describe new medications for the treatment
More informationPauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters?
International Journal of Rheumatic Diseases 2016; 19: 74 81 ORIGINAL ARTICLE Pauci-immune glomerulonephritis: does negativity of antineutrophilic cytoplasmic antibodies matters? Aman SHARMA, 1, * Ritambra
More informationDisclosures. Objectives. Vasculitis: What The Primary Care Physician Needs To Know. Definition & Classification of Vasculitis
Vasculitis: What The Primary Care Physician Needs To Know Lynn Fussner, MD Assistant Professor - Clinical Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationVasculitis: What The Primary Care Physician Needs To Know. Lynn Fussner, MD
Vasculitis: What The Primary Care Physician Needs To Know Lynn Fussner, MD Assistant Professor - Clinical Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationManagement of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe
Management of Acute Vasculitis CMT teaching 3 rd June 2015 Caroline Wroe Vasculitis pub quiz Match the date with the event Dr Peter McBride, Scottish Otolaryngologist describes a disease of rapid destruction
More informationa mimicker of Wegener s Granulomatosis
a mimicker of Wegener s Granulomatosis Combined Meeting October 2009 a story of 2 ladies Madam JA 56 year-old Madam RH 36 year-old Madam JA 56 year-old Apr 2008 May Jun Jul Aug Sept Oct Nov 2008 Madam
More informationA prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature
478 Bispebjerg Hospital, 2400 Copenhagen NV, Denmark S F Sørensen Hvidovre Hospital, Hvidovre, Denmark O Slot N Tvede Rigshospitalet, National University Hospital, Copenhagen, Denmark J Petersen Correspondence
More informationGene expression profiling in ANCA-vasculitis renal biopsies
Gene expression profiling in ANCA-vasculitis renal biopsies Marcia Friedman, MD Northwest Rheumatism Society Meeting OHSU Fellow Research Presentation April 29 th 2017 Disclosures I have no disclosures
More informationTreatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2015;41:296301 Received: March 12, 2015 Accepted: May 6, 2015 Published online: June 2, 2015 Treatment
More informationDr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Vasculitis Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Disease Spectrum Hypersensitivity vasculitis/microscopic
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. José María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. José María Pego Reigosa ABSTRACT NUMBER: 2754 Comparison of Individually Tailored vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions:
More informationEULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis
EULAR recommendations for clinical trials in vasculitis 1 EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis Bernhard
More informationCirculating complement activation in patients with anti-neutrophil cytoplasmic antibody associated vasculitis
http://www.kidney-international.org & 212 International Society of Nephrology see commentary on page 16 Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody associated
More information